https://orcid.org/0000-0003-3080-9356
References
- Smithson S, Pignone MP. Screening adults for depression in primary Care. Med Clin N Am. 2017;101:807–821. DOI:10.1016/j.mcna.2017.03.010.
- Hen-Shoval D, Weller A, Weizman A, et al. Examining the use of antidepressants for adolescents with depression/anxiety who regularly use cannabis: a narrative review. Int J Envir Res Public Health. 2022;19(1):523.
- Zuardi AW. History of cannabis as a medicine: a review. Braz J Psychiatry. 2006;28(2):153–157.
- Weinberger AH, Zhu J, Lee J, et al. Cannabis use among youth in the United States, 2004–2016: faster rate of increase among youth with depression. Drug Alcohol Depend. 2020;209:107894.
- Kuhathasan N, Minuzzi L, MacKillop J, et al. An investigation of cannabis use for insomnia in depression and anxiety in a naturalistic sample. BMC Psychiatry. 2022;22(1):303.
- Kosiba JD, Maisto SA, Ditre JW. Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: systematic review and meta-analysis. Soc Sci Med. 2019;233:181–192.
- Mangoo S, Erridge S, Holvey C, et al. Assessment of clinical outcomes of medicinal cannabis therapy for depression: analysis from the UK medical cannabis registry. Expert Rev Neurother. 2022;22(11–12):995–1008.
- Round JM, Lee C, Hanlon JG, et al. Changes in patient health questionnaire (PHQ-9) scores in adults with medical authorization for cannabis. BMC Public Health. 2020;20(1):987.
- Vickery AW, Roth S, Ernenwein T, et al. A large Australian longitudinal cohort registry demonstrates sustained safety and efficacy of oral medicinal cannabis for at least two years.PLoS ONE. 2022 [Published 2022 Nov 18];17(11):e0272241. DOI:10.1371/journal.pone.0272241.
- Gilman JM, RM S, KW P, et al. Effect of medical marijuana card ownership on pain, insomnia, and affective disorder symptoms in adults: a randomized clinical trial. JAMA Netw Open. 2022;5(3):e222106.